Lanier Biotherapeutics
Ryan Hallett is an accomplished professional in the biotechnology sector with extensive experience in product development and management. Currently serving as Vice President of Product Development at Lanier Biotherapeutics and working as an Independent Consultant for Life Science Startups in the Southeast Region, Ryan also holds the position of Chief Executive Officer and Co-founder at Dualogics since December 2017, where expertise is utilized in creating bispecific antibody therapeutics through the OrthoMab platform. Ryan previously co-founded Dualogics LLC and contributed as Chief Operating Officer from February 2015 to December 2017. Early in the career, Ryan gained extensive research experience as a Postdoctoral Researcher and Graduate Research Assistant at the University of North Carolina at Chapel Hill and as a Research Technician at the University of Florida. Academic qualifications include a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and a B.S. in Chemistry with a focus on Biochemistry from the University of Florida.
This person is not in any teams
This person is not in any offices
Lanier Biotherapeutics
Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases.